Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles
Abstract
:1. Introduction
2. Materials and Methods
2.1. SapC Preparation and Purification
2.2. Synthesis and Characterization of Iodinated SapC-DOPS Nanovesicles
2.3. Iodination of Phenolic Compounds with Iodine-127
2.4. Incorporation of the Compounds into SapC-DOPS and Targeting GBM Cells
2.5. Radioiodination of the Compounds
2.6. Analysis of 131I Incorporation into Phenolic DiD (16,16) by Thin Layer Chromatography (TLC)
2.7. Assembly of SapC-DOPS Nanovesicles with 131I Radioiodinated Phenolic DiD (16,16)
2.8. Pharmacokinetic Studies with 125I-DiI (22,3)- and 125I-DiD (16,16)-SapC-DOPS
2.9. Efficacy Studies with 131I-DiD (16,16)-SapC-DOPS
3. Results
3.1. Chemical and Physical Properties of the Iodinated Compounds
3.2. Phenolic Dye Uptake by Brain Tumor Cells and Pharmacokinetics
3.3. Radioiodinated SapC-DOPS Improved Survival of Brain Tumor-Bearing Mice
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Dolecek, T.A.; Propp, J.M.; Stroup, N.E.; Kruchko, C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012, 14 (Suppl. 5), v1–v49. [Google Scholar] [CrossRef]
- Bleeker, F.E.; Molenaar, R.J.; Leenstra, S. Recent advances in the molecular understanding of glioblastoma. J. Neuro Oncol. 2012, 108, 11–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005, 2, 3–14. [Google Scholar] [CrossRef]
- de Vries, N.A.; Beijnen, J.H.; Boogerd, W.; van Tellingen, O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother. 2006, 6, 1199–1209. [Google Scholar] [CrossRef] [PubMed]
- Lacroix, M.; Abi-Said, D.; Fourney, D.R.; Gokaslan, Z.L.; Shi, W.; Demonte, F.; Lang, F.F.; McCutcheon, I.E.; Hassenbusch, S.J.; Holland, E.; et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95, 190–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walker, M.D.; Alexander, E., Jr.; Hunt, W.E.; Maccarty, C.S.; Mahaley, M.S.; Mealey, J.; Norrell, H.A.; Owens, G.; Ransohoff, J.; Wilson, C.B.; et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 1978, 49, 333–343. [Google Scholar] [CrossRef] [Green Version]
- Fulton, D.S.; Urtasun, R.C.; Scott-Brown, I.; Johnson, E.; Mielke, B.; Curry, B.; Huyser-Wierenga, D.; Hanson, J.; Feldstein, M. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J. Neurooncol. 1992, 14, 63–72. [Google Scholar] [CrossRef]
- Khosla, D. Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann. Transl. Med. 2016, 4, 54. [Google Scholar]
- Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; A Brandes, A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [Google Scholar] [CrossRef]
- Shenouda, G.; Souhami, L.; Petrecca, K.; Owen, S.; Panet-Raymond, V.; Guiot, M.-C.; Corredor, A.G.; Abdulkarim, B. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 2017, 97, 487–494. [Google Scholar] [CrossRef] [PubMed]
- Fabian, D.; Guillermo Prieto Eibl, M.D.P.; Alnahhas, I.; Sebastian, N.; Giglio, P.; Puduvalli, V.K.; Gonzalez, J.; Palmer, J.D. Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Cancers (Basel) 2019, 11, 174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760. [Google Scholar] [CrossRef]
- Provenzale, J.M.; Silva, G.A. Uses of nanoparticles for central nervous system imaging and therapy. AJNR Am. J. Neuroradiol. 2009, 30, 1293–1301. [Google Scholar] [CrossRef] [Green Version]
- Qi, X.; Chu, Z.; Mahller, Y.Y.; Stringer, K.F.; Witte, D.P.; Cripe, T.P. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin. Cancer Res. 2009, 15, 5840–5851. [Google Scholar] [CrossRef] [Green Version]
- Abu-Baker, S.; Chu, Z.; Stevens, A.M.; Li, J.; Qi, X. Cytotoxicity and Selectivity in Skin Cancer by SapC-DOPS Nanovesicles. J. Cancer Ther. 2012, 3, 321–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blanco, V.M.; Chu, Z.; Vallabhapurapu, S.D.; Sulaiman, M.K.; Kendler, A.; Rixe, O.; Warnick, R.E.; Franco, R.S.; Qi, X. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget 2014, 5, 7105–7118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blanco, V.M.; Curry, R.; Qi, X. SapC-DOPS nanovesicles: A novel targeted agent for the imaging and treatment of glioblastoma. Oncoscience 2015, 2, 102–110. [Google Scholar] [CrossRef] [Green Version]
- Chu, Z.; Abu-Baker, S.; Palascak, M.B.; Ahmad, S.A.; Franco, R.S.; Qi, X. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS ONE 2013, 8, e75507. [Google Scholar] [CrossRef] [Green Version]
- N’Guessan, K.F.; Davis, H.W.; Chu, Z.; Vallabhapurapu, S.D.; Lewis, C.S.; Franco, R.S.; Olowokure, O.; Ahmad, S.A.; Yeh, J.J.; Bogdanov, V.Y.; et al. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Mol. Ther. 2020, 18, 1876–1886. [Google Scholar] [CrossRef]
- N’Guessan, K.F.; Patel, P.H.; Qi, X. SapC-DOPS—A Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy. Cell Commun. Signal. 2020, 18, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Winter, P.M.; Pearce, J.; Chu, Z.; McPherson, C.M.; Takigiku, R.; Lee, J.-H.; Qi, X. Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine. J. Magn. Reson. Imaging 2015, 41, 1079–1087. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kolter, T.; Sandhoff, K. Lysosomal degradation of membrane lipids. FEBS Lett. 2010, 584, 1700–1712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Riedl, S.; Rinner, B.; Asslaber, M.; Schaider, H.; Walzer, S.; Novak, A.; Lohner, K.; Zweytick, D. In search of a novel target—Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim. Biophys. Acta 2011, 1808, 2638–2645. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Webb, B.A.; Chimenti, M.; Jacobson, M.P.; Barber, D.L. Dysregulated pH: A perfect storm for cancer progression. Nat. Rev. Cancer 2011, 11, 671–677. [Google Scholar] [CrossRef]
- Zhao, S.; Chu, Z.; Blanco, V.M.; Nie, Y.; Hou, Y.; Qi, X. SapC-DOPS nanovesicles as targeted therapy for lung cancer. Mol. Cancer Ther. 2015, 14, 491–498. [Google Scholar] [CrossRef] [Green Version]
- Blanco, V.M.; Chu, Z.; LaSance, K.; Gray, B.D.; Pak, K.Y.; Rider, T.; Greis, K.D.; Qi, X. Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles. Oncotarget 2016, 7, 32866–32875. [Google Scholar] [CrossRef]
- Chu, Z.; LaSance, K.; Blanco, V.; Kwon, C.-H.; Kaur, B.; Frederick, M.; Thornton, S.; Lemen, L.; Qi, X. In vivo optical imaging of brain tumors and arthritis using fluorescent SapC-DOPS nanovesicles. J. Vis. Exp. 2014, 2, 51187. [Google Scholar] [CrossRef] [Green Version]
- Rixe, O.; Morris, J.M.; Puduvalli, V.K.; Villano, J.L.; Wise-Draper, T.M.; Muller, C.; Johnson, A.N.; Wesolowsik, R.; Qi, X. First-in-human, first-in-class phase 1a study of BXQ for solid tumors and gliomas. J. Clin. Oncol. 2018, 36, 2517. [Google Scholar] [CrossRef]
- AbdelBaki, M.; Setty, B.; DeWire, M.D.; Cripe, T.P.; Curry, R. A pediatric and young adult phase I dose escalation study of BXQ-350 for solid and central nervous system tumors. J. Clin. Oncol. 2020, 38, 2541. [Google Scholar] [CrossRef]
- Wojton, J.; Meisen, W.H.; Jacob, N.K.; Thorne, A.H.; Hardcastle, J.; Denton, N.; Chu, Z.; Dmitrieva, N.; Marsh, R.; Van Meir, E.G.; et al. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget 2014, 5, 9703–9709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, Y.; Liou, B.; Chu, Z.; Fannin, V.; Blackwood, R.; Peng, Y.; Grabowski, G.A.; Davis, H.W.; Qi, X. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine 2020, 55, 102735. [Google Scholar] [CrossRef] [PubMed]
- Davis, H.W.; Vallabhapurapu, S.D.; Chu, Z.; Vallabhapurapu, S.L.; Franco, R.S.; Mierzwa, M.; Kassing, W.; Barrett, W.L.; Qi, X. Enhanced Phosphatidylserine-selective Cancer Therapy with Irradiation and SapC-DOPS Nanovesicles. Oncotarget 2019, 10, 856–868. [Google Scholar] [CrossRef] [Green Version]
- Kaimal, V.; Chu, Z.; Mahller, Y.Y.; Papahadjopoulos-Sternberg, B.; Cripe, T.P.; Holland, S.K.; Qi, X. Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol. Imaging Biol. 2011, 13, 886–897. [Google Scholar] [CrossRef] [PubMed]
- Middendorp, M.; Grünwald, F. Update on recent developments in the therapy of differentiated thyroid cancer. Semin. Nucl. Med. 2010, 40, 145–152. [Google Scholar] [CrossRef] [PubMed]
- Dekempeneer, Y.; Keyaerts, M.; Krasniqi, A.; Puttemans, J.; Muyldermans, S.; Lahoutte, T.; D’Huyvetter, M.; Devoogdt, N. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin. Biol. Ther. 2016, 16, 1035–1047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Green, D.J.; Orgun, N.N.; Jones, J.C.; Hylarides, M.D.; Pagel, J.M.; Hamlin, D.K.; Wilbur, D.; Lin, Y.; Fisher, D.R.; Kenoyer, A.L.; et al. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res. 2014, 74, 1179–1189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qi, X.; Leonova, T.; Grabowski, G.A. Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J. Biol. Chem. 1994, 269, 16746–16753. [Google Scholar]
- Kopia, G.A.; Horan, P.K.; Gray, B.D.; Troutner, D.E.; Muirhead, K.A.; Sheth, K.A.; Lin, C.-E.; Yu, Z.; Jensen, B.D.; Slezak, S.E. Compounds, Compositions and Methods for Binding Bio-Affecting Substances to Surface Membranes of Bio-Particles. U.S. Patent No. 5,667,764, 16 September 1997. [Google Scholar]
- Wojton, J.; Chu, Z.; Mathsyaraja, H.; Meisen, W.H.; Denton, N.; Kwon, C.-H.; Chow, L.M.L.; Palascak, M.; Franco, R.; Bourdeau, T.; et al. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013, 21, 1517–1525. [Google Scholar] [CrossRef] [Green Version]
- Pak, C.C.; Fidler, I.J. Molecular mechanisms for activated macrophage recognition of tumor cells. Semin. Cancer Biol. 1991, 2, 189–195. [Google Scholar]
- Lambin, P. Might intrinsic radioresistance of human tumour cells be induced by radiation? Int. J. Radiat. Biol. 1996, 69, 279–290. [Google Scholar] [CrossRef] [PubMed]
Synonym | CalcMass | ObsMass | Purity at 260 nm (AUC) | Purity at 550 nm (AUC) | Retention Time (min) | Abs Max (nm) | FL Ex Max (nm) | ε (M−1cm−1) |
Phenolic-DiI(22,22) | 1123 | 1123.4 | 94.60% | 100% | 16.1 | 555 | 571 | 134,100 |
Phenolic-DiI(22,14) | 1010.8 | 1010.6 | 98.50% | 100% | 14.7 | 555 | 571 | 143,400 |
Phenolic-DiI(22,3) | 856.7 | 856.3 | 82.40% | 100% | 13.6 | 555 | 570 | 118,800 |
Phenolic-DiI(16,16) | 954.8 | 954.9 | 90.90% | 100% | 14.3 | 556 | 571 | 133,100 |
Synonym | CalcMass | ObsMass | Purity at 260 nm (AUC) | Purity at 650 nm (AUC) | Retention Time (min) | Abs Max (nm) | FL Ex Max (nm) | ε (M−1cm−1) |
Phenolic-DiD(14,22) | 1036.9 | 1036.9 | 98.10% | 99.50% | 14.2 | 652 | 670 | 222,200 |
Phenolic-DiD(22,3) | 882.7 | 882.7 | 97.40% | 100% | 13.6 | 651 | 671 | 235,600 |
Phenolic-DiD(16,16) | 980.8 | 981.6 | 96.20% | 100% | 12.8 | 652 | 671 | 227,500 |
DiI (22,3) | DiD (16,16) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacokinetic Parameters | 1 | 2 | 3 | Mean of PK Values | PK Values of Mean Conc | Pharmacokinetic Parameters | 1 | 2 | 3 | Mean of PK Values | PK Values of Mean Conc |
Time to Peak (Tmax) (h) | 0.5 | 1 | 0.5 | 0.66 ± 0.28 | 1 | Time to Peak (Tmax) (h) | 4 | 4 | 4 | - | 4 |
Cpmax (Peak conc) (cpm/mL) | 48.3 | 35.8 | 46.1 | 43.4 ± 6.67 | 40.1 | Cpmax (Peak conc) (cpm/mL) | 30.1 | 26.8 | 33.7 | 30.2 ± 3.4 | 30.23 |
Elimination HalfLife (h) | 10.69 | 9.58 | 6.11 | 8.79 ± 2.38 | 8.39 | Elimination HalfLife (h) | 7.27 | 22.67 | 8.96 | 12.96 ± 8.4 | 11.5 |
AUC0-24 (cpm.hr/mL) | 442 | 204 | 462 | 369 ± 143 | 370 | AUC0-24 (cpm.h/mL) | 446 | 496 | 506 | 482 ± 32 | 482 |
AUC0-t (cpm.hr/mL) | 552 | 240 | 491 | 427 ± 165 | 422 | AUC0-t (cpm.h/mL) | 494 | 967 | 600 | 687 ± 248 | 624 |
Volume of Distribution/F | 69,424 | 142,902 | 44,613 | 85,646 ± 51,113 | 71,284 | Volume of Distribution/F | 52,845 | 84,271 | 53,614 | 63,576 ± 17,925 | 64,239 |
Systemic Clearance/F (mL/h) | 4500 | 10,337 | 5058 | 6631 ± 3221 | 5885 | Systemic Clearance/F (mL/h) | 5033 | 2575 | 4147 | 3918 ± 1244 | 3991 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Davis, H.W.; Vallabhapurapu, S.D.; Chu, Z.; Wyder, M.A.; Greis, K.D.; Fannin, V.; Sun, Y.; Desai, P.B.; Pak, K.Y.; Gray, B.D.; et al. Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles. Cells 2020, 9, 1960. https://doi.org/10.3390/cells9091960
Davis HW, Vallabhapurapu SD, Chu Z, Wyder MA, Greis KD, Fannin V, Sun Y, Desai PB, Pak KY, Gray BD, et al. Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles. Cells. 2020; 9(9):1960. https://doi.org/10.3390/cells9091960
Chicago/Turabian StyleDavis, Harold W., Subrahmanya D. Vallabhapurapu, Zhengtao Chu, Michael A. Wyder, Kenneth D. Greis, Venette Fannin, Ying Sun, Pankaj B. Desai, Koon Y. Pak, Brian D. Gray, and et al. 2020. "Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles" Cells 9, no. 9: 1960. https://doi.org/10.3390/cells9091960